The roles of brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) in predicting treatment remission in a Chinese Han population with generalized anxiety disorder

Shen, Zhongxia; Zhu, Jiang; Yuan, Yonggui; Ren, Lie; Qian, Mincai; Lin, Min Jon; Min, Cai; Zhang, Zhen; Shen, Xinhua

doi:10.1016/j.psychres.2018.08.111

Cited by 31 publications

(23 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the HPA axis is dysregulated also in GAD [138], no consistent results can be drawn with respect to the peripheral biomarkers, with some studies showing an increase, while others a decrease in the investigated biomarkers, at the baseline or after the stress test/treatments. BDNF showed some consistent results (reduction of basal levels in some reports [210,220,223,224]), likely supporting its role in different ADs and encouraging further investigation [218]. In PDA, several studies showed an increase in the peripheral biomarkers related to the noradrenergic system [35,49,[51][52][53], underlining an abnormal noradrenergic system regulation with consequent pathological clinical expression.…”

Section: Discussionmentioning

confidence: 68%

“…Some neurotropic factors showed a predictive value in treatment response. In GAD patients, a reduction in the BDNF levels followed a symptoms remission (after treatment with paroxetine) [224] and the NGF serum levels, after successful CBT, increased significantly [227]. Moreover, in PDA, a lower serum BDNF level was associated with an inadequate treatment response to CBT [229].…”

Section: Discussionmentioning

confidence: 99%

“…By contrast, significantly lower BDNF plasma levels in GAD patients vs. the HCs emerged in other reports [210,223,224]. Shen and colleagues observed higher baseline plasma BDNF levels in GAD patients vs. controls and a normalization after GAD remission (patients were treated with paroxetine) [225].…”

Section: General Anxiety Disordersmentioning

confidence: 93%

“…General anxiety disorder BDNF Plasma levels =vs. HCs, ↓ in females [220,221] No association with disorder severity [222] ↓ vs. HCs [210,223,224] ↑ vs. HCs, with normalization after remission [225] BDNF levels in the newborn's cord blood of women with GAD ↑ vs. HCs [226] NGF Serum levels =vs. HCs at baseline, ↑ after remission [227] GDNF Serum BDNF/GDNF levels ↓ vs. HCs [228] Panic disorders with or without agoraphobia BDNF Plasma levels =vs.…”

Section: Biomarker Findingmentioning

confidence: 99%

“…Some studies combined BDNF and glial cell-derived neurotrophic factor (GDNF) to explore their relationship with GAD, investigating the characteristics of serum and their potentials to predict treatment remission in GAD patients [224,228]. Indeed, serum BDNF/GDNF levels were lower in GAD patients compared to HCs and, specifically, females showed higher BDNF/GDNF levels compared to males [224]. According to these authors, the gender-related influence might be related to the influence of menstrual cycle, considering that most of the subjects included were female in the menopausal period.…”

Section: General Anxiety Disordersmentioning

confidence: 99%

See 4 more Smart Citations

Peripheral Biomarkers in DSM-5 Anxiety Disorders: An Updated Overview

et al. 2020

View full text Add to dashboard Cite

Anxiety disorders are prevalent and highly disabling mental disorders. In recent years, intensive efforts focused on the search for potential neuroimaging, genetic, and peripheral biomarkers in order to better understand the pathophysiology of these disorders, support their diagnosis, and characterize the treatment response. Of note, peripheral blood biomarkers, as surrogates for the central nervous system, represent a promising instrument to characterize psychiatric disorders, although their role has not been extensively applied to clinical practice. In this report, the state of the art on peripheral biomarkers of DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th edition) Anxiety Disorders is presented, in order to examine their role in the pathogenesis of these conditions and their potential application for diagnosis and treatment. Available data on the cerebrospinal fluid and blood-based biomarkers related to neurotransmitters, neuropeptides, the hypothalamic–pituitary–adrenal axis, neurotrophic factors, and the inflammation and immune system are reviewed. Despite the wide scientific literature and the promising results in the field, only a few of the proposed peripheral biomarkers have been defined as a specific diagnostic instrument or have been identified as a guide in the treatment response to DSM-5 Anxiety Disorders. Therefore, further investigations are needed to provide new biological insights into the pathogenesis of anxiety disorders, to help in their diagnosis, and to tailor a treatment.

show abstract